Novo Nordisk fell over 1% premarket as investors prepared for a contentious vote to reinstate former CEO Lars Rebien Sorensen as chairman. His return follows a board rupture that triggered mass resignations over strategic disagreements. Though the outcome is assured due to the Foundation’s 77% voting control, minority shareholders and ISS have raised governance and transparency concerns.